Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

981 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Kircik LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani AR, Draelos ZD, DuBois J, Gooderham MJ, Kempers SE, Lain E, Lee M, Moore A, Murrell DF, Papp KA, Pariser DM, Sinclair R, Zirwas M, Burnett P, Higham RC, Krupa D, Berk DR. Kircik LH, et al. Among authors: sinclair r. Br J Dermatol. 2023 Sep 15;189(4):392-399. doi: 10.1093/bjd/ljad182. Br J Dermatol. 2023. PMID: 37279795 Clinical Trial.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J. Zhou C, et al. Among authors: sinclair r. J Am Acad Dermatol. 2023 Nov;89(5):911-919. doi: 10.1016/j.jaad.2023.02.063. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019385 Clinical Trial.
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Wynne CJ, Cole A, Lemech C, Wang G, Zhang Y, Chen B, Wang M, Li B, Xia M, Sinclair R. Wynne CJ, et al. Among authors: sinclair r. Dermatol Ther (Heidelb). 2023 Oct;13(10):2357-2373. doi: 10.1007/s13555-023-01010-1. Epub 2023 Sep 5. Dermatol Ther (Heidelb). 2023. PMID: 37668898 Free PMC article.
Rosacea Fulminans following Initiation of Deucravacitinib.
Thomas M, Paranjape M, Sinclair R. Thomas M, et al. Among authors: sinclair r. Clin Exp Dermatol. 2024 Nov 15:llae495. doi: 10.1093/ced/llae495. Online ahead of print. Clin Exp Dermatol. 2024. PMID: 39545490 No abstract available.
981 results